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Asymmetric total synthesis of (+)-epilupinine was achieved in just 3 steps using only commercially available common reagents. 
The total synthesis involved alkylations of N-nosylamide, ozone oxidation, and sequential reactions of the removal of the nosyl 
group, intramolecular dehydrative condensation, intramolecular Mannich reaction catalyzed by L-proline, and a reduction.
Quinolizidine alkaloids, which have the octahydro-2H-quino-
lizine (quinolizidine) skeleton as a structural unit, are second-
ary metabolites found mostly in genus Lupinus and are 
known to exhibit various potent biological activities that are 
mainly cytotoxicity.1 (+)-Epilupinine (1), structurally one of the 
simplest quinolizidine alkaloids, was initially considered the 
epimerized product of (+)-lupinine2 but was later isolated as 
a natural secondary metabolite from various members of the 
lupin family.3 1 has been known to exhibit in vitro inhibitory 
activity against Leukaemia P-388 and lymphocytic Leukae-
mia L1210.4 Recent studies elucidated that the structure of 1 
incorporated into various drugs plays an important role as a 
pharmacophore.5 For example, the (+)-epilupinine moiety of 
antiviral and antimalarial drugs is suggested to behave as a 
ligand of 5-HT3, 5-HT4, and sigma receptors.6 Therefore, 1 
has received a great deal of attention from synthetic organic 
chemists due to its potent and diverse biological activities 
and simple but synthetically cumbersome structure. So far, 
15 asymmetric total syntheses of epilupinine4,7 and more 
than 30 racemic total syntheses8 have been reported. Alt-
hough these include efficient chiral syntheses, there remain 
several points in need of improvement in the use of an ex-
pensive chiral auxiliary, other steps for the synthesis of start-
ing materials, cumbersome separation from diastereomer 
and byproducts, longer number of steps, and so on, respec-
tively. The biosynthetic pathway of (+)-epilupinine (1) is con-
sidered to include the cascade reaction of intramolecular de-
hydrative condensation and the Mannich reaction (4→2 in 
Scheme 1),9 and Van Tamelen and Foltz actually synthe-
sized (±)-epilupinine based on the biomimetic cascade re-
action in 1960.8o However, development of asymmetric ver-
sion of this cascade reaction that would be the most efficient 
approach to (+)-epilupinine has not been achieved for around 
60 years since their racemic total synthesis despite many 
successful examples of asymmetric total synthesis. Herein, 
we report a development of its asymmetric version and a re-
markably simple total synthesis of (+)-epilupinine (1) in just 3 
steps from commercially available common reagents as 
starting materials. 
Scheme 1. Synthetic Plan of (+)-Epilupinine (1) 
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Our synthetic plan for 1 is outlined in Scheme 1. (+)-
Epilupinine (1) will be readily obtained by the reduction of the 
aldehyde moiety of 2. The aldehyde 2 would be obtained by 
the Mannich reaction of 3. In this reaction, the addition of a 
chiral secondary amines as an organocatalyst is expected to 
give optically active 2 via an enamine aldol-type reaction. The 
iminium salt 3 would be formed by the intramolecular dehy-
drative condensation of either of the aldehydes of 4 with a 
secondary amine resulting from the deprotection of the nosyl 
group. It is noteworthy that removal of the nosyl group in the 
presence of asymmetric catalyst followed by reduction in one 
pot is expected to directly give (+)-1 from 5 via the biomimetic 
cascade reaction.  
To investigate the optimal conditions for the cas-
cade reaction, we synthesized the dialdehyde 5 as the pre-
cursor (Scheme 2). Treatment of N-nosylamide 6 with 2.0 
equiv of 6-bromo-1-hexene 7 and K2CO3 in DMF at 100 °C 
afforded the diene 8 in 98% yield. Ozone oxidation of the 
diene 8 in dichloromethane at -78 °C proceeded smoothly to 
give the dialdehyde 5 in 86% yield. The dialdehyde 5 was 
sufficiently stable for purification by silica gel column chroma-
tography. 
Scheme 2. Synthesis of Cascade Reaction Precursor 5.  
  
Having prepared precursor 5, we next examined the 
cascade reaction from 5 to 2. Since the cyclization product 2 
is unstable and volatile, the aldehyde 2 was reduced directly 
to epilupinine 1 by adding NaBH4 and methanol to the reac-
tion mixture, and then the yield and ee were determined.10 
First, we tried various organocatalysts (A, B, C, G, H, I) in 
methanol, obtaining epilupinine 1 in low yield (6 ~ 29%) with 
modest ee (< 5 ~ 59%) after direct reduction of 2 (see Sup-
porting Information). Although the cascade reaction pro-
ceeded as expected, optimization to increase yield and ee 
was required. When the solvent effect on the cascade reac-
tion catalyzed by Jørgensen’s catalyst A was investigated,11 
the use of CHCl3 was found to increase the chemical yield, 
although almost no ee was appeared (Table 1, entry 1 and 
Supporting Information). Therefore, we further optimized the 
conditions of the cascade reaction in CHCl3 (Table 1). 
Whereas the addition of MacMillan’s catalyst B7c,12 did not 
give 1 (entry 2), Hayashi-Jørgensen catalyst C13 substantially 
increased the ee (61%) with good chemical yield (73%) (entry 
3).  However, increasing catalyst C to 50 mol% did not im-
prove either yield or ee (entry 4). The related catalysts D14 
and E15 showed declines in yield, and almost no ee was ob-
served (entries 5 and 6). In addition, the reaction using cata-
lyst F16 or the prolineamide G17 did not afford 1 (entries 7 and 
8). On the other hand, the use of D-proline H18 as the catalyst 
provided an enantiomer of 1 in 57% yield with 26% ee (entry 
9), and increasing the amount of H to 100 mol% elevated 
both yield and ee (entry 10). Since the reaction using D-pro-
line predominantly afforded (-)-epilupinine, L-proline was 
used in subsequent investigation. To further increase the ee, 
a similar reaction using L-proline was conducted at 0 °C, and 
the ee of (+)-1 increased to 76% (entry 11). However, further 
decreasing the temperature to -15 °C induced declines in 
both yield and the ee (entry 12). Next, when we changed the 
base from K2CO3 to Cs2CO3, the ee fortunately increased to 
83% (entry 13).19 In addition, the use of previously prepared 
cesium salt J further improved the ee to 92% (entry 14).19 
However, several trials on multi-gram scale showed 84~86% 
ee, even when cesium salt J was used. Although the ee de-
creased in gram-scale synthesis, reproducibility over 83% ee 
was ensured. Thus, we adopted the condition of entry 13 for 
gram-scale synthesis in terms of chemical yield, ee, and con-
venience, because the 83% ee can be further increased by 
recrystallization. On the other hand, the use of Triton B as 
another base having a bulky counter cation decreased the ee 
(entry 15), and Li2CO3 and Me4NOH did not give 1 (entries 
16 and 17). Throughout the optimization study, we did not 
detect the formation of diastereomers. Probably, the dia-
stereomers of 2 was readily epimerized under basic condi-
tions. Although we further examined the reaction conditions 
such as additives, the ee could not be increased above 92% 
(Supporting Information).  













1 A (20) K2CO3 rt 71 <5 
2 B (20) K2CO3 rt - - 
3 C (20) K2CO3 rt 73 61 
4 C (50) K2CO3 rt 61 59 
5 D (20) K2CO3 rt 33 <5 
6 E (20) K2CO3 rt 28 8
c 
 
7 F (20) K2CO3 rt trace 11 
8 G (20) K2CO3 rt - - 
9 H (20) K2CO3 rt 57   30
d,e 
10 H (100) K2CO3 rt 68 69
d 
11 I (100) K2CO3 0 61 76 
12 I (100) K2CO3 -15 38  28
e 
13f I (100) Cs2CO3 0 70 83 
14 J (100) Cs2CO3 0 35 92 
15 I (100) Triton B 0 53  25e 
16 I (100) Li2CO3 0 - - 
17 I (100) Me4NOH 0 - - 
 
aThe reaction was performed by using 35 mg (0.095 mmol) 
of 5. bIsolated yield. cEe was measured by the integral ratio 
of 19F NMR after converting 1 to the corresponding Mosher’s 
ester according to the conventional method. dEe of (-)-
epilupinine (enantiomer) is described. eEe was determined 
from specific optical rotation. f5.0 g (13.5 mmol) of 5 was 
used.  
Next, we tried to increase the ee by recrystallization. Due 
to the low recovery rate of free 1 from recrystallization, we 
tried to recrystallize 1 in a salt form. Among various acids 
such as carboxylic, sulfonic, and hydrochloric acids,20 we 
found that triphenylacetic acid forms a good solid salt with 
epilupinine. Then, (+)-epilupinine triphenylacetic acid salt 
was sufficiently recrystallized from CHCl3 and diethyl ether, 
and the resulting crystals were treated with acid-base distri-
bution to afford salt-free (+)-epilupinine 1 in 53% yield as an 
enantiomerically pure form.21 Thus, enantiomerically pure 
(+)-epilupinine (1) was obtained by our three-step total syn-
thesis22and the efficient single step construction of (+)-
epilupinine 1 from dialdehyde 5 was established. 
We studied the enantioselectivity of a proline-catalyzed in-
tramolecular Mannich reaction under Cs2CO3 condition by 
Density Functional Theory (DFT) calculation (Figure 1 and 
supporting information). Taking the adduct of proline-acti-
vated Cs-salt of iminium cation (A, A’ and A’’) as a model 
substrate, we calculated the transition states for the intramo-
lecular asymmetric Mannich reaction to form a C1-C2 bond. 
Our calculation result showed that the attack from the less-
hindered Si-face of the sp2 carbon C2 in the 6-membered ring 
of the iminium cation through TSSi is favored and the reaction 
is exergonic, resulting in (+)-epilupinine. However, its oppo-
site enantiomer resulting from the Re-face attack at C2 
needed a high-energy barrier of 5.36 kcal/mol through TSRe 
(Figure 1). The transition state TSSi is stabilized by the for-
mation of low-energy 6-membered ring with an O--H interac-
tion between H of C2 and O of carboxylate group of the cat-
alyst I (Figure 1). The transition state lacks such interaction 
in the case of opposite enantiomer.  In addition, the transition 
state for formation of one of its diastereomer (TS’) has lower 
energy barrier of 3.63 kcal/mol compared to TSRe, however, 
we obtained only enantiomer 1’ and 1 may be due to the epi-
merization of aldehyde to the most stable conformer that 
leads to the formation of (+) epilupinine 1. We also compared 
the reaction profile taking K-salt. The calculation showed that 
the distance between C1 and C2 in the transition state TSSi 
is 2.55 Å (Cs-salt) and 2.50 Å (K-salt) respectively; and the 
gap of activation energy between TSRe and TSSi is higher in 
the case of Cs-salt than K-salt due to stronger O--H interac-
tion (O-H distance for Cs-salt is 2.88 Å and for K-salt is 3.22 
Å respectively) (Figure 1 and supporting information). This 




Figure 1. a) Mode of attack on C2 by nucleophilic C1. b) En-
ergy profile diagram for formation of enantiomers and dias-
teromers of Epilupinine using catalyst I. c) optimized transi-
tion states for the Mannich reaction. 
 
Finally, we applied the established condition for (+)-
epilupinine (1) to the synthesis of related natural products 
such as (+)-tashiromine (10) and (+)-trachelanthamidine (12) 
that include azabicyclo [4,3,0] and [3.3.0] skeletons, respec-
tively. However, although the similar reaction of 9 afforded 
racemic tashiromine 10 in 23% yield.23 In addition, multi prod-
ucts were obtained in the case of 11, and the isolation of (+)-
trachelanthamidine (12) was difficult. Further optimization is 
needed for these related natural products. 
Scheme 3. Application of the cascade reaction to related 
quinolizidine alkaloids. 
 
In conclusion, a three-step total synthesis of (+)-epilupinine 
from commercially and readily available common reagents 
was established. The total synthesis consists of two alkyla-
tions of N-nosylamide, ozone oxidation, the cascade reaction 
of two cyclizations, and a reduction. The cascade reaction 
includes deprotection of the nosyl group, intramolecular imin-
ium cation formation, and the intramolecular asymmetric 
Mannich reaction. In the asymmetric Mannich reaction, L-
proline cesium salt was found to give the highest enantio-
meric excess. Although a stoichiometric amount of L-proline 
was needed for high ee, L-proline is not an expensive or-
ganocatalyst and is recoverable from the reaction mixture. 
Furthermore, we discovered the recrystallization condition of 
1 so that enantiomerically pure (+)-epilupinine is readily ob-
tained by this synthesis. Although there have been over 45 
examples of the synthesis of epilupinine, there are fewer 
steps in this synthesis than in any conventional synthesis, 
even including racemic total synthesis. On the other hand, 
the application of this asymmetric cascade reaction to other 
related natural products from genus Lupinus is next chal-
lenge, because the application to the synthesis of (+)-ta-
shiromine and (+)-trachelanthamidine did not give good re-
sults. Further development of the resulting quinolizidine ana-
logs as the functional molecules is currently underway in our 
laboratory. 
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